Belite Bio (BLTE) CEO Lin Yu‑Hsin Sells 100,435 Shares

What Happened
Lin Yu‑Hsin, CEO of Belite Bio, sold a total of 100,435 American Depositary Shares (ADSs) in multiple open‑market transactions on September 4 and September 8, 2026. The individual sale prices ranged from $180.29 to $198.09, generating total gross proceeds of approximately $19,082,548 (weighted average ≈ $189.91 per ADS). The sales were effected pursuant to a Rule 10b5‑1 trading plan adopted on December 23, 2025. These were outright sales (S) — routine dispositions rather than purchases.

Key Details

• Transaction dates: 2026-09-04 and 2026-09-08. Price range: $180.29–$198.09. Total shares sold: 100,435. Total proceeds: ~$19.08M. Weighted average price ≈ $189.91/ADS.
• Notable individual batches (examples): 11,080 ADSs at $191.15 ($2,117,909); 8,955 ADSs at $189.34 ($1,695,552); 8,752 ADSs at $197.36 ($1,727,275).
• Sales executed under a Rule 10b5‑1 plan (footnote F2 — plan adopted 12/23/2025). ADS info: each ADS represents one ordinary share (footnote F1).
• Several footnotes (F3–F21) indicate weighted average prices for grouped sales and that the reporting person will provide per‑price breakdowns upon request.
• Shares owned after the transactions are not included in the provided excerpt. The filing does not indicate a late filing flag.

Context

• These were open‑market sales under an established 10b5‑1 plan, which typically allows insiders to sell shares according to a pre‑arranged schedule and is generally considered a routine liquidity event rather than a direct signal of confidence or concern.
• For retail investors, purchases by insiders are often more informative than routine sales; this filing documents significant monetization by the CEO but does not, by itself, indicate a change in company fundamentals.